Browse Hospital Articles by Topic

APIC Raises IP Profile on YouTube

For many years, patients, the public, and even some fellow healthcare workers were not fully aware of the critical role IPs played behind the scenes. The IP profile has been raised dramatically over the last decade by national efforts to reduce healthcare-associated infections, the rise of antibiotic resistance, and emerging infections like Ebola. As a result, APIC created a video that features IPs explaining what they do and what aspects of the job they particularly enjoy. The video can be used to raise awareness among the public, patients, medical personnel, and recruit new IPs into the profession.

Infection Prevention Expertise Lacking on Water Management Teams

Water management plans to control Legionella and other waterborne pathogens in healthcare settings have become a priority since a CMS memo in 2017 ordered such measures to protect patients. Infection preventionists should be a key member of these water management teams, but almost half the facilities consulted by Legionella experts did not have an IP on the committee.

CMS Deadline Nears, But Infection Control in Long-Term Care a Challenge

The churn of staff turnover and administrative changes in long-term care may make it difficult for many facilities to meet an impending federal requirement to establish infection prevention programs. The CMS deadline for a designated and trained infection preventionist in long-term care facilities is Nov. 28, 2019. CMS and the CDC are offering free training to meet this requirement, but there are signs that some long-term care facilities will struggle to comply.

MERS Still a Threat in Saudi Arabia

Although it has not been sustained in other countries following introductions and outbreaks, Middle East Respiratory Syndrome (MERS) coronavirus has established an endemic presence in the Kingdom of Saudi Arabia since it emerged in 2012, the World Health Organization reports. As of June 30, 2019, there have been 2,449 laboratory-confirmed cases of MERS reported, with 84% in Saudi Arabia and the rest in 27 other countries, including the United States. There have been 845 MERS deaths, resulting in a mortality rate of 35%.

CDC Gears Up as Ebola Outbreak Escalates in Africa

The CDC is stepping up efforts to fight an Ebola outbreak that is threatening to spread beyond the borders of the Democratic Republic of Congo (DRC). The World Health Organization recently declared an international health emergency in DRC after an Ebola case appeared July 14 in Goma, a city of 2 million people that has connecting flights to global air travel. As of Aug. 2, there have been four cases in Goma.

The ‘Vaccine Wars:’ Will Science Prevail?

In a year marked by more than 1,000 infections with a disease that once was eradicated in the United States, the tide of public opinion may be turning against the antivaccine movement. Measles resurgence coincides with parents citing unsafe vaccines as a reason not to immunize their children. However, there is a growing pushback against the antivaccine movement, with herd immunity threatened and the real risk of measles to immunocompromised patients and those who cannot be immunized.

Indigenous People Grill NIH on All of Us Protections

Attempting to reassure an indigenous community that has been abused in past research, the NIH All of Us precision medicine initiative is holding a series of meetings and webinars with the National Congress of American Indians. A key part of the dialogue is letting American Indian/Alaska Native Tribal Nations ask questions and express concerns about the project.

Identifiable Data Are Not What They Used to Be

IRBs and researchers should change their old habits when it comes to assessing studies for privacy and confidentiality. Researchers recently showed that de-identified data could be used to find a specific person. Using a mathematical model in databases of more than 200 populations, researchers found they could correctly re-identify 99.98% of Americans, using 15 demographic attributes.

Tips for IRBs Reviewing Pragmatic Trials

Flexibility is needed when reviewing pragmatic clinical trials, which typically enroll a broader population of patients and might need more adaptable informed consent than traditional clinical trials. Researchers have raised questions about how pragmatic trials should be regulated and what IRBs should do to protect participants, but not discourage this type of research.

Pragmatic Trials on the Rise as Data Collection Pushes Trend

Several recent changes are driving the pragmatic trial trend nationally, including acceptance from regulators and the growth of big data. Pragmatic clinical trials measure effectiveness of a study drug, device, or intervention on a wider range of people. Unlike clinical trials that exclude people based on health conditions and other criteria, pragmatic trials study a treatment’s effect on a group of people who are more representative of patients in clinical practice and the real world.